BEAM

Beam Therapeutics Inc. NMS · BEAM

$26.75 -0.54 (-1.98%)

Pullback · -1.84σ

+ Compare Open in Sniper

Mkt cap $2.8B

P/E —

Day $26.61 – $27.17

52wk $21.63 – $38.26

Avg vol 2.4M

Beta 2.18

Div yld —

Next earnings 2026-08-04

Quick read

At a glance

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.

BEAM last traded at $26.75, down 2.0% on the day; that's in the lower part of its 52-week range ($21.63–$38.26). Right now it's dipped below its recent average — a spot where watchers often look for signs the dip is stabilizing.

The next scheduled earnings report (2026-08-04) is the biggest known catalyst on the calendar, and after the recent dip, watch whether the price stops making lower lows before assuming the worst is over.

A quick snapshot built from the data on this page — not investment advice. Always do your own research.

Today's read

Grading desk →

Price is stretched slightly below its normal range — a light stretch — early days, worth watching.

Long —

Setup score 17 / 100

Price is stretched slightly below its normal range — a light stretch — early days, worth watching.

· KC1 lower stretch — light dip

Technical read: KC1 lower, -1.79 ATR from EMA21 · no notable pattern

What it means: Price is stretched slightly below its normal range — a light stretch — early days, worth watching. The trigger bar shows no standout candle signal yet.

Score split: chart signals 17 / 80 · news & fundamentals checks 0 / 20 — chart signals carry most of the grade.

How this grade was earned

total 17 pts

Cycle position 14

Market fit 3

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

Short —

Setup score 12 / 100

Price is sitting close to its normal range — not meaningfully overheated yet.

· Aligned with weak downtrend

Technical read: below KC1 upper, -1.79 ATR from EMA21 · no notable pattern

What it means: Price is sitting close to its normal range — not meaningfully overheated yet. The trigger bar shows no standout candle signal yet.

Score split: chart signals 12 / 80 · news & fundamentals checks 0 / 20 — chart signals carry most of the grade.

How this grade was earned

total 12 pts

Cycle position 6

Market fit 6

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

132-Day Trend Zones

Full chart →

21 EMA +1 ATR +2 ATR −2 ATR

—

O — H — L — C —

— —

Under the hood

On the latest daily bar, momentum sits mid-range (RSI 35), the trend is quiet (ADX 24), and trading is light at 0.2× normal volume. On the business side, revenue is growing 325% year over year and the business keeps about -167 cents of every sales dollar as free cash.

Latest-bar indicator readings behind the grade — display-only, they don't move the letter.

Momentum · RSI

0–100 · <30 oversold

Trend strength · ADX

>25 = strong trend

Volume vs avg

0.17×

1× = average

Stretch from avg

-1.7 ATR

− below · + above

Zone touches

tests of this zone

Suggested hold

3–30

bars (≈ days)

Fundamentals at a glance

Company fundamentals for context — display-only, they don't move the grade.

Revenue growth

+324.9%

year over year

Free-cash-flow margin

-167.1%

cash kept per $ of sales

Debt / equity

0.22

lower = less leveraged

Valuation & accounting

Valuation desk →

The model's verdict is “Unknown” and accounting quality screens as Weak. Model estimates only — do your own due diligence.

Unknown Accounting: Weak

Fair-value range

$4.07 – $4.07

Accounting quality Weak

✓ More cash than debt
✓ Current ratio 13.09 (antifragile)
✓ Debt/equity 0.20 (antifragile)

⚠ Negative retained earnings
⚠ Stock comp 67% of revenue (heavy dilution)

Key statistics

All statistics →

BEAM is a $2.8 billion company, it moves harder than the market (beta 2.2).

Market cap $2.8B

P/E ttm —

Beta 2.18

52w range $21.63 – $38.26

Avg volume 2.4M

Dividend yield —

Sector Healthcare

Next earnings 2026-08-04

52-week range · today's price

$21.63$38.26

More on BEAM

Options idea

See more →

CALL $28 2026-08-21

$2.18

PUT $28 2026-08-21

$3.25

Earnings

See more →

Last reported: 2026-05-07
EPS (act / est): -0.91 / -1.01
Surprise: +10.1%
Next report: 2026-08-04

About

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEA…